Pharmaceuticals

Revenue of the Gastroparesis Drugs Market Predicted to Achieve $7.37 Billion by 2030, Driven by 5.2% CAGR

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gastroparesis drugs market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Gastroparesis Drugs Market?

The gastroparesis drugs market size has experienced significant expansion in recent years. This market is set to increase from $5.7 billion in 2025 to $6.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. The market’s growth in the past can be attributed to factors such as the increasing diagnosis of diabetic gastroparesis, the long-standing use of prokinetic and antiemetic drugs, the growing prevalence of diabetes-related gastrointestinal disorders, the availability of both otc and prescription symptom relief medications, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $7.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period stems from several factors, including the increasing worldwide prevalence of diabetes, heightened recognition of gastroparesis as a chronic ailment, a surging requirement for potent long-term symptom management, broader availability of specialized gastrointestinal care, and a continuous necessity for enhanced motility-improving therapies. Key trends expected during this period involve an increasing dependence on prokinetic agents for managing symptoms, a rise in the application of combination drug therapies for gastroparesis, a heightened call for prescription-only gastroparesis medications, the broadening of treatment strategies concentrated on specific symptoms, and a more extensive adoption of oral drug formulations for extended care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Drivers Are Supporting The Rise Of The Gastroparesis Drugs Market?

The increasing prevalence of diabetes is anticipated to stimulate the expansion of the gastroparesis drugs market moving forward. Diabetes is a chronic metabolic condition defined by high blood sugar levels, which result from either insufficient insulin creation or impaired insulin use. The rise in diabetes cases is attributed to sedentary lifestyles, unhealthy dietary choices, genetic predispositions, increasing urbanization, aging populations, and rising obesity rates. The gastroparesis drugs market plays a crucial role in diabetes care by providing medications that mitigate symptoms like nausea, vomiting, and delayed gastric emptying, which are frequent gastrointestinal complications associated with diabetic gastroparesis. A notable example occurred in March 2024, when the Office for Health Improvement & Disparities, a UK-based government department, reported that from March 2022 to March 2023, the number of individuals with type 1 diabetes undergoing all eight recommended care processes increased by 22%, while for type 2 diabetes patients, there was a 21% rise, and the proportion achieving target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit. Therefore, the growing incidence of diabetes is indeed fostering the development of the gastroparesis drugs market.

What Leading Segments Are Studied In The Gastroparesis Drugs Market?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What Trends Are Projected To Support The Growth Of The Gastroparesis Drugs Market?

Companies operating within the gastroparesis drugs market are actively developing innovative solutions, such as novel prokinetic therapies, to enhance gastric motility and alleviate symptoms. These new prokinetic therapies are medications designed to stimulate and improve the stomach and intestines’ normal movement, aiding more effective food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for the filing of its New Drug Application (NDA) for tradipitant, intended for treating gastroparesis symptoms. This approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, to address gastroparesis, a serious digestive disorder with significant unmet medical needs. This acceptance represents a crucial regulatory milestone for Vanda as it continues its efforts to secure marketing authorization for tradipitant for gastroparesis patients.

Which Leading Companies Dominate The Gastroparesis Drugs Market Share?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

How Does The Gastroparesis Drugs Market Perform Across Major Global Regions?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastroparesis Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795